{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:20Z","timestamp":1790720360390,"version":"4.1.0"},"reference-count":32,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,4,28]]},"published-print":{"date-parts":[[2026,8]]},"DOI":"10.2967\/jnumed.125.270573","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:40:11Z","timestamp":1780584011000},"page":"1239-1246","source":"Crossref","is-referenced-by-count":1,"title":["Dosimetry Results from the Phase 1b\/3 ACTION-1 Trial of [\n                    <sup>225<\/sup>\n                    Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor\u2013Expressing, Well-Differentiated GEP-NETs"],"prefix":"10.2967","volume":"67","author":[{"given":"George","family":"Sgouros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Ulaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Kotiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Sneeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2026082505101659000_67.8.1239.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21493"},{"key":"2026082505101659000_67.8.1239.2","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.3390\/jcm9113655","article-title":"Emerging treatment options for gastroenteropancreatic neuroendocrine tumors","volume":"9","author":"Cives","year":"2020","journal-title":"J Clin Med."},{"key":"2026082505101659000_67.8.1239.3","doi-asserted-by":"crossref","first-page":"e2124750","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA. Netw Open."},{"key":"2026082505101659000_67.8.1239.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"2026082505101659000_67.8.1239.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0397-7"},{"key":"2026082505101659000_67.8.1239.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"2026082505101659000_67.8.1239.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2026082505101659000_67.8.1239.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2026082505101659000_67.8.1239.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2026082505101659000_67.8.1239.10","unstructured":"Sgouros G . MIRD Monograph: Radiobiology and Dosimetry for Radiopharmaceutical Therapy with Alpha-Particle Emitters. SNMMI; 2015."},{"key":"2026082505101659000_67.8.1239.11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026082505101659000_67.8.1239.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264043"},{"key":"2026082505101659000_67.8.1239.13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/rssc.12089","article-title":"Bayesian optimal interval designs for phase I clinical trials","volume":"64","author":"Liu","year":"2015","journal-title":"J R Stat Soc Ser C Appl Stat."},{"key":"2026082505101659000_67.8.1239.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0592"},{"key":"2026082505101659000_67.8.1239.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.056036"},{"key":"2026082505101659000_67.8.1239.16","doi-asserted-by":"publisher","DOI":"10.1177\/0146645315613480"},{"key":"2026082505101659000_67.8.1239.17","unstructured":"Clinical Trials Facilitation Group. Recommendations related to contraception and pregnancy testing in clinical trials. Heads of Medicines Agencies website. www.hma.eu\/fileadmin\/dateien\/Human_Medicines\/01-About_HMA\/Working_Groups\/CTFG\/2014_09_HMA_CTFG_Contraception.pdf. Accessed May 11, 2026."},{"key":"2026082505101659000_67.8.1239.18","first-page":"7","article-title":"ICRP publication 107: nuclear decay data for dosimetric calculations","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann ICRP."},{"key":"2026082505101659000_67.8.1239.19","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1109\/NSSMIC.1996.591559","article-title":"A new method for modeling the spatially-variant, object-dependent scatter response function in SPECT","volume":"2","author":"Frey","year":"1996","journal-title":"1996 IEEE Nucl Sci Symp Conf Rec"},{"key":"2026082505101659000_67.8.1239.20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","article-title":"111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med."},{"key":"2026082505101659000_67.8.1239.21","doi-asserted-by":"publisher","DOI":"10.1109\/42.363108"},{"key":"2026082505101659000_67.8.1239.22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2026082505101659000_67.8.1239.23","doi-asserted-by":"crossref","first-page":"235015","DOI":"10.1088\/1361-6560\/abbc7e","article-title":"Specific absorbed fractions and radionuclide S-values for tumors of varying size and composition","volume":"65","author":"Olguin","year":"2020","journal-title":"Phys Med Biol."},{"key":"2026082505101659000_67.8.1239.24","doi-asserted-by":"publisher","DOI":"10.1118\/1.1288393"},{"key":"2026082505101659000_67.8.1239.25","unstructured":"Snyder WS Ford MR Warner GG Watson SB . \u201cS,\u201d absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD pamphlet no. 11. SNMMI website. https:\/\/snmmi.org\/common\/Uploaded%20files\/Downloadable%20PDF\/MIRD\/MIRD%20Pamphlet%20No.%2011.pdf. Published October 1975. Accessed May 11, 2026."},{"key":"2026082505101659000_67.8.1239.26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1109\/TNS.2002.1039549","article-title":"Parameterization of Pb X-ray contamination in simultaneous Tl-201 and Tc-99m dual-isotope imaging","volume":"49","author":"Wang","year":"2002","journal-title":"IEEE Trans Nucl Sci."},{"key":"2026082505101659000_67.8.1239.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000596"},{"key":"2026082505101659000_67.8.1239.28","doi-asserted-by":"publisher","DOI":"10.2307\/3574096"},{"key":"2026082505101659000_67.8.1239.29","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/56\/3\/012"},{"key":"2026082505101659000_67.8.1239.30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3390\/cancers14041055","article-title":"Radiolabeled somatostatin analogues for diagnosis and treatment of neuroendocrine tumors","volume":"14","author":"Ambrosini","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2026082505101659000_67.8.1239.31","unstructured":"Novartis. Highlights of prescribing information Lutathera (lutetium Lu 177 dotatate) injection. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/lutathera.pdf. Accessed October 18, 2024."},{"key":"2026082505101659000_67.8.1239.32","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2024.42.16_suppl.3091","article-title":"Phase Ib portion of the ACTION-1 phase Ib\/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: safety and efficacy findings [abstract]","volume":"42","author":"Halperin","year":"2024","journal-title":"J Clin Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:10:32Z","timestamp":1787659832000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.2967\/jnumed.125.270573"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270573","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}